BioAge Labs, Inc (BIOA) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $8.01 (-0.99%), Market cap $0.79B, 52-week low–high $3.90 ~ $22.92.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company
Financial statements, price targets, institutional (13F) holdings and related news for BioAge Labs, Inc are updated in real time on BlackAll Trade.
BioAge Labs, Inc trades at $8.01 (-0.99%). Real-time quotes and charts are available on BlackAll Trade.
BioAge Labs, Inc has a market cap of about $0.79B.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that